Matteo Lambertini, MD PhD· @matteolambe · X·· 2 天前评分90
正文 · 原文
Oral abstract #BreastCancer session at #ESMO26: updated data from the TALENT trial showing activity of neoadjuvant #TrastuzumabDeruxtecan in HER2-low HR+ disease
@OncoAlert @myESMO
542 浏览 · 20 赞 · 10 转发 · 0 回复
会议摘要
LBA23按 Proffered paper 1: Breast cancer, early and advanced stage 对上
Final results of TALENT: A neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer
https://esmocongress.esmo.org来源：Matteo Lambertini, MD PhD · x.com